Paper34072068
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.
Martino M and 16 others. Cancers (Basel), 2021. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. Papers, record 34072068. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34072068
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33321731 | The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma. | Pharmaceuticals (Basel) | 2020 | https://conductscience.org/library/papers/33321731 | PubMed |
| 2 | 32961764 | Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. | J Clin Med | 2020 | https://conductscience.org/library/papers/32961764 | PubMed |
| 3 | 32729730 | Antibody-drug conjugates for multiple myeloma. | Expert Opin Biol Ther | 2021 | https://conductscience.org/library/papers/32729730 | PubMed |
| 4 | 33275747 | Future of CAR T cells in multiple myeloma. | Hematology Am Soc Hematol Educ Program | 2020 | https://conductscience.org/library/papers/33275747 | PubMed |
| 5 | 32989217 | Multiple myeloma current treatment algorithms. | Blood Cancer J | 2020 | https://conductscience.org/library/papers/32989217 | PubMed |
| 6 | 33303615 | Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. | Science | 2020 | https://conductscience.org/library/papers/33303615 | PubMed |
| 7 | 33089218 | Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. | Blood Cancer Discov | 2020 | https://conductscience.org/library/papers/33089218 | PubMed |
| 8 | 33368165 | Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy. | Br J Haematol | 2021 | https://conductscience.org/library/papers/33368165 | PubMed |
| 9 | 23344265 | B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23344265 | PubMed |
| 10 | 29605883 | Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia. | Cancer Immunol Immunother | 2018 | https://conductscience.org/library/papers/29605883 | PubMed |
| 11 | 32221812 | Memory T cells: strategies for optimizing tumor immunotherapy. | Protein Cell | 2020 | https://conductscience.org/library/papers/32221812 | PubMed |
| 12 | 33285522 | Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 | https://conductscience.org/library/papers/33285522 | PubMed |
| 13 | 32516895 | BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32516895 | PubMed |
| 14 | 33227097 | T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. | Oncotarget | 2020 | https://conductscience.org/library/papers/33227097 | PubMed |
| 15 | 28361085 | Human stem memory T cells (TSCM) as critical players in the long-term persistence of immune responses. | Ann Transl Med | 2017 | https://conductscience.org/library/papers/28361085 | PubMed |
| 16 | 32943087 | BCMA-targeted immunotherapy for multiple myeloma. | J Hematol Oncol | 2020 | https://conductscience.org/library/papers/32943087 | PubMed |
| 17 | 33272302 | Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. | J Hematol Oncol | 2020 | https://conductscience.org/library/papers/33272302 | PubMed |
| 18 | 33383757 | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. | Pharmaceuticals (Basel) | 2020 | https://conductscience.org/library/papers/33383757 | PubMed |
| 19 | 32875817 | Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. | Future Oncol | 2020 | https://conductscience.org/library/papers/32875817 | PubMed |
| 20 | 28928126 | Chimeric antigen receptor T-cell therapies for multiple myeloma. | Blood | 2017 | https://conductscience.org/library/papers/28928126 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42662940 | The landscape and trajectory of global CRISPR therapeutics. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42662940 | PubMed |
| 42375474 | Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics. | Mol Ther Adv | 2026 | https://conductscience.org/library/papers/42375474 | PubMed |
| 42345736 | Quality of Life in CAR-T Cell Therapy. | Hematol Rep | 2026 | https://conductscience.org/library/papers/42345736 | PubMed |
| 41335261 | Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/41335261 | PubMed |
| 41283232 | The Gut Microbiome Role in Multiple Myeloma: Emerging Insights and Therapeutic Opportunities. | Hematol Rep | 2025 | https://conductscience.org/library/papers/41283232 | PubMed |
| 40304075 | Prognostic and biological characteristics associated with multiple myeloma presenting only with anemia. | Haematologica | 2025 | https://conductscience.org/library/papers/40304075 | PubMed |
| 39844764 | The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy. | Haematologica | 2025 | https://conductscience.org/library/papers/39844764 | PubMed |
| 39502704 | Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy. | Front Immunol | 2024 | https://conductscience.org/library/papers/39502704 | PubMed |
| 39313307 | BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma. | J Immunother Cancer | 2024 | https://conductscience.org/library/papers/39313307 | PubMed |
| 39130943 | Exploring Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated Protein 9 (CRISPR-Cas9) as a Therapeutic Modality for Cancer: A Scoping Review. | Cureus | 2024 | https://conductscience.org/library/papers/39130943 | PubMed |
| 39091493 | CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects. | Front Immunol | 2024 | https://conductscience.org/library/papers/39091493 | PubMed |
| 38862983 | Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy. | Cell Commun Signal | 2024 | https://conductscience.org/library/papers/38862983 | PubMed |
| 38756776 | Effectiveness of CAR-T treatment toward the potential risk of second malignancies. | Front Immunol | 2024 | https://conductscience.org/library/papers/38756776 | PubMed |
| 38672686 | Immune Therapies in AL Amyloidosis-A Glimpse to the Future. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38672686 | PubMed |
| 38616952 | Educational Case: Multiple myeloma. | Acad Pathol | 2024 | https://conductscience.org/library/papers/38616952 | PubMed |
| 38152777 | Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-cell Therapy: A Retrospective Study Analyzing Risks, Outcomes, and Healthcare Burden. | Cureus | 2023 | https://conductscience.org/library/papers/38152777 | PubMed |
| 37668832 | Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11. | Int J Hematol | 2023 | https://conductscience.org/library/papers/37668832 | PubMed |
| 37569693 | CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37569693 | PubMed |
| 37296856 | Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37296856 | PubMed |
| 36612152 | How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36612152 | PubMed |
Genes21
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34072068
GET https://conductscience.org/api/papers/v1/34072068/references?page=2